Prometheus Biosciences, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Prometheus Biosciences, Inc. | RXDX - NASDAQ |
$18.00-$19.00 | $19.00 | $24.95 | 10 million | 3/12/2021 |
| SVB Leerink, Credit Suisse, Stifel, Guggenheim Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-02-19 Terms Added 2021-03-08 Amended Terms 2021-03-11 | ||||||
Prometheus Biosciences, Inc. Quote & Chart - Click for current quote - RXDX
IPO Boutique aggregates information on public companies and private companies, such as "RXDX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Prometheus Biosciences, Inc. (adapted from Prometheus Biosciences, Inc. prospectus):
They are a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD).
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD).
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "RXDX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.